Eli Lilly shares climbed 3.1% in morning trading as the American Diabetes Association’s 86th Scientific Sessions opened in New Orleans, putting the company’s most consequential pipeline data in recent years under a public microscope.
The centrepiece of Lilly’s presentations is retatrutide, an investigational triple-receptor agonist. Lilly released Phase 3 TRIUMPH-1 results showing an average weight loss of 70.3 lbs, equivalent to 28.3% of body weight over 80 weeks. The company has compared these outcomes to bariatric surgery. Full data from TRIUMPH-1 are being shown publicly for the first time at the conference, giving investors fresh confirmation of the drug’s potential to create a new category in obesity treatment.
Simultaneously, Lilly is presenting Phase 3 findings for Foundayo, its oral GLP-1 pill. The presentations cover three diabetes studies in which Foundayo demonstrated superiority versus existing oral therapies. These efficacy readouts add to the momentum from the obesity program.
Commercial developments accompanied the clinical news. CVS Caremark announced it will place both Zepbound and Foundayo on its formulary. That move completes coverage by the three largest U.S. pharmacy benefit managers for Lilly’s full obesity drug lineup, a milestone that materially expands patient access and removes a key commercial overhang.
Analysts have reacted with continued bullishness. Morgan Stanley reiterated an Overweight rating and maintained a $1,344 price target for Lilly. TD Cowen raised its forecast for the global GLP-1 market to $150 billion by 2030. William Blair analyst Andy Hsieh described retatrutide as, given its high potency, a drug in a "different drug category," a characterization that appears to have resonated with investors.
The move in Lilly shares stood in sharp contrast to broader market weakness. The S&P 500 was down 1.0%, the Nasdaq fell 1.9%, and the Dow slipped 0.3% during the same session, underlining that the rally was driven by company-specific developments rather than a market-wide rebound.
Lilly’s primary rival, Novo Nordisk, is also presenting data at ADA 2026, but the combination of the TRIUMPH-1 readout, Foundayo’s diabetes results, expanded formularies and supportive analyst notes concentrated investor attention on Lilly. The stock reached a new 52-week intraday high of $1,161.97, illustrating how focused pipeline execution can overcome broader macro headwinds in a risk-off session.
Market context
- Company-specific clinical and commercial catalysts pushed LLY higher while major indexes lagged.
- Key pipeline data for retatrutide and Foundayo were presented publicly at ADA for the first time.
- All three largest U.S. PBMs now cover Lilly’s obesity drug portfolio following CVS Caremark’s announcement.